Lipanthyl Micronisé (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, which regulates genes involved in fatty‑acid oxidation and lipoprotein metabolism. By enhancing the breakdown of triglycerides and increasing the activity of lipoprotein lipase, it promotes clearance of triglyceride‑rich particles and modestly raises HDL‑cholesterol, leading to an overall better lipid profile.

The appropriate dose of Lipanthyl Micronisé is determined by the prescribing healthcare professional based on the individual’s clinical condition, laboratory results, and concomitant therapies. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without altering the regimen on their own.

Safety data for fenofibrate in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To request Lipanthyl Micronisé, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Fenofibrate belongs to the fibric acid class, which primarily lowers triglycerides and modestly raises HDL‑cholesterol. Statins, the most common alternative, mainly reduce LDL‑cholesterol and have a broader evidence base for cardiovascular event reduction. In patients with severe hypertriglyceridaemia, fenofibrate may be preferred, while statins are often first‑line for LDL‑cholesterol management.

Store Lipanthyl Micronisé at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct light. Do not refrigerate or freeze the product, and ensure it is kept out of reach of children.

Lipanthyl Micronisé is taken orally, usually once daily with a meal to enhance absorption. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional. Consistency with food intake helps maintain stable drug levels.

The most serious adverse events linked to fenofibrate include rhabdomyolysis (muscle breakdown that can lead to kidney failure), severe liver injury such as hepatitis or hepatic failure, and rare hypersensitivity reactions like angioedema. Patients should be monitored for muscle pain, unexplained fatigue, jaundice, or signs of an allergic reaction and report them promptly.

Fenofibrate is contraindicated in individuals with active liver disease, severe renal impairment, known gallbladder disease, or a history of hypersensitivity to fenofibrate or other fibric acid derivatives. It should also be avoided in patients taking gemfibrozil or other medications that significantly increase the risk of myopathy.